Enoxaparin 40 mg Versus 60 mg for Venous Thromboembolism Prophylaxis After Bariatric Surgery: A Systematic Review and Meta-Analysis of Pharmacologic and Clinical Outcomes
Mahmoud Albashier, Ibrahim Moqbel, Ahmad Omar Saleh, Rawan Kamal Mohammed, Mohammad Mahadin, Mohamed Hany Ezz, Mahmoud Omar Dakhly, Yahya A Mahmoud, Hosam Elghadban · 2026
Read Enoxaparin 40 mg Versus 60 mg for Venous Thromboembolism Prophylaxis After Bariatric Surgery: A Systematic Review and Meta-Analysis of Pharmacologic and Clinical Outcomes by Mahmoud Albashier, Ibrahim Moqbel, Ahmad Omar Saleh, Rawan Kamal Mohammed, Mohammad Mahadin, Mohamed Hany Ezz, Mahmoud Omar Dakhly, Yahya A Mahmoud, Hosam Elghadban (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13323224.txt.
Description
Mahmoud Albashier leads a review comparing two enoxaparin doses after bariatric surgery, published in 2026, for preventing venous blood clots. Obesity changes how this blood thinner behaves in the body, so the standard 40 mg dose may under-protect surgical patients.
Following PRISMA guidance, the team searched five databases to September 2025 for trials and cohort studies of 40 mg against 60 mg dosing. Ten studies with 1,276 patients qualified. The main outcome was reaching target anti-factor Xa levels, with clots, bleeding, deaths and other complications also tracked. Random-effects pooling compared drug levels and clinical events, aiming to judge whether higher dosing protects without added bleeding harm.
Catalog record
| CREATOR | Mahmoud Albashier, Ibrahim Moqbel, Ahmad Omar Saleh, Rawan Kamal Mohammed, Mohammad Mahadin, Mohamed Hany Ezz, Mahmoud Omar Dakhly, Yahya A Mahmoud, Hosam Elghadban |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54913 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |